Nikolai Petrovsky | Chairman
Vaxine Pty.
Nikolai Petrovsky is a physician scientist with research interests in vaccines, adjuvants and immuno-informatics. He is currently a Professor of Immunology and Infectious Disease at the Australian Respiratory and Sleep Medicine Institute and a Research Professor at the Institute of Molecular Medicine in California. He is Research Director of Vaxine Pty Ltd, an Australian biotechnology company known for its innovative adjuvants and for developing SpikoGen® vaccine, a protein-based COVID-19 vaccine in use in the Middle East. He developed CpG55.2, the first licensed human drug product created by artificial intelligence. He has been PI on multiple US National Institutes of Health contracts and has authored over 300 peer-reviewed research papers and reviews.
Appearances:
Pre-Congress Workshops - 21st April @ 10:00
Alternative Vaccine Targets Workshop
ALTERNATIVE VACCINE TARGETS [AM3] – 10am – 1pm
Exploring the development of vaccines against non-infectious disease targets.
10am Workshop leaders opening remarks: Dr Jay Evans, CSO, InImmune; Director, Center for Translational Medicine, University of Montana
10.10am Clinical development of immunotherapies for allergy
Dr Jay Evans, CSO, InImmune; Director, Center for Translational Medicine, University of Montana
10.40am Advancing a vaccine targeting C9orf72 ALS to the clinical stage
Dr Robert van der Put, Director Business Development, Intravacc
11.10am Adjuvant centric development of overdose preventing vaccines targeting fentanyl
Dr David Dowling, Assistant Professor of Pediatrics, Harvard Medical School; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital
Dr. Shon Remich, MD, and CMO, Ovax
11.40am Development of adjuvanted vaccines for allergy and Alzheimer’s and drug addiction
Dr Nikolai Petrovsky, Chairman, Vaxine Pty Ltd.
12:10pm Panel Discussion –What are the unique challenges of getting non-traditional target vaccines to market?
· Ethics of challenge studies
· Alternatives to animal models
· Regulatory challenges
· Considerations for designing & planning trials
· Funding
Moderator: Dr Jay Evans, CSO, InImmune; Director, Center for Translational Medicine, University of Montana
Dr Robert van der Put, Director Business Development, Intravacc
Dr David Dowling, Assistant Professor of Pediatrics, Harvard Medical School; Precision Vaccine Program, Division of Infectious Diseases, Boston Children's Hospital
Dr. Shon Remich, MD, and CMO, ARMR Science
Dr Nikolai Petrovsky, Chairman, Vaxine Pty Ltd.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events